• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

First uveitis patient treated with Eyevensys’ electro-transfection system

May 9, 2017 By Sarah Faulkner

EyevensysPrivate biotech Eyevensys said today that it treated the 1st patient in a first-in-human phase I/II trial of its lead candidate, EYS606, for the treatment of non-infectious uveitis. The patient was treated in Paris at the Cochin Institute using the company’s EyeCET technology.

The EyeCET platform is an electro-transfection injection system that delivers non-viral plasmids to encode for disease-specific therapeutic proteins in the ciliary muscle of the eye. Eyevensys’ lead product delivers a plasmid that encodes for the production of a protein to treat non-infectious uveitis.

The 24-patient trial aims to evaluate the safety and tolerability of the treatment. The procedure takes less than 5 minutes, according to Eyevensys, and is designed to eliminate the need for monthly injections.

Eyevensys said it expects initial results from the dose escalation study in the 1st half of 2018.

“Successfully treating our 1st patient is an important step towards improving outcomes for patients with NIU,” founder & chief scientific officer Francine Behar-Cohen said in prepared remarks. “This is the first time plasmid DNA has been successfully delivered to the eye via electro-transfection. This represents a major milestone for Eyevensys and a key step in validating the potential of our EyeCET platform to provide safe and long-lasting treatments for patients while avoiding the current standard of multiple injections and their associated safety risks.”

“I am delighted to be part of this landmark clinical study using Eyevensys’ unique EyeCET platform,” principal investigator Antoine Brézin added. “This 1st treatment was very well tolerated by the patient, which represents an important step towards potentially improving outcomes for patients with NIU. NIU is a rare and severe eye condition afflicting approx. 25,000 in France and there is a critical need for novel treatments.”

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Optical/Ophthalmic Tagged With: Eyevensys

IN CASE YOU MISSED IT

  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling
  • Senseonics stock is up as it sticks by revenue guidance
  • Rapid Dose closes first tranche of $5M financing

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS